SREBF1 and metabolic syndrome: NAR has also demonstrated the ability to reduce and prevent dyslipidemia by increasing fatty acid oxidation by activating PPAR-γ and preventing SREBP1-mediated lipogenesis by reducing hyperinsulinemia and decreasing VLDL-c [56].